Literature DB >> 19926120

Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology.

Paola Narducci1, Renato Bareggi, Vanessa Nicolin.   

Abstract

The strength and integrity of the human skeleton depends on a delicate equilibrium between bone resorption and bone formation. Bone resorption is an elementary cellular activity in the modelling of the skeleton during growth and development. Later in life a most important physiological process in the skeleton is bone remodelling, which is locally initiated by resorption. During remodelling bone resorption is coupled to new bone formation that ensures renewal of bone with only minor local and temporary bone loss. Cells responsible for bone resorption and subsequent bone formation are the osteoclasts and osteoblasts, respectively. The osteoclast is derived from the pluripotent hematopoietic stem cell, which gives rise to a myeloid stem cell that can further differentiate into megakaryocytes, granulocytes, monocytes/macrophages and osteoclasts. The respective bone resorbing and forming actions of osteoclasts and osteoblasts are finely coupled, so that bone mass remains remarkably stable in a healthy adult. Imbalance between osteoclast and osteoblast activities can arise from a wide variety of hormonal changes or perturbations of inflammatory and growth factors resulting in postmenopausal osteoporosis, Paget's disease, lytic bone metastases, or rheumatoid arthritis, leading to increased bone resorption and crippling bone damage. In view of the critical role of osteoclasts in diverse pathology, there has been immense effort aimed at understanding the biology of this unique cell. The present review is focused on the current knowledge of the mechanisms that regulate the functional links between bone turnover and the immune system helping us to understand the main factors that lead to bone loss observed in osteoporosis, cancer and in rheumatoid arthritis. The aim of this review paper is to consider the key molecular interactions involved in the formation of osteoclast cells in normal and pathological conditions.
Copyright © 2009 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19926120     DOI: 10.1016/j.acthis.2009.10.003

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  5 in total

Review 1.  A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.

Authors:  Yunes Panahi; Amir Hossein Mohammadzadeh; Behzad Behnam; Hossein M Orafai; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.

Authors:  Diana Carmona-Fernandes; Maria José Santos; Inês Pedro Perpétuo; João Eurico Fonseca; Helena Canhão
Journal:  Arthritis Res Ther       Date:  2011-10-25       Impact factor: 5.156

3.  Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report.

Authors:  Maria Guadalupe Zavala-Cerna; Maria Cristina Moran-Moguel; Jesus Alejandro Cornejo-Toledo; Norma Guadalupe Gonzalez-Montoya; Jose Sanchez-Corona; Mario Salazar-Paramo; Arnulfo Hernan Nava-Zavala; Erika Anita Aguilar-Chavez; Miriam Fabiola Alcaraz-Lopez; Alicia Guadalupe Gonzalez-Sanchez; Laura Gonzalez-Lopez; Jorge Ivan Gamez-Nava
Journal:  J Immunol Res       Date:  2015-05-03       Impact factor: 4.818

Review 4.  Osteoclast-Derived Extracellular Vesicles: Novel Regulators of Osteoclastogenesis and Osteoclast-Osteoblasts Communication in Bone Remodeling.

Authors:  Feng-Lai Yuan; Qian-Yuan Wu; Zong-Ning Miao; Ming-Hui Xu; Rui-Sheng Xu; Dong-Lin Jiang; Jun-Xing Ye; Fei-Hu Chen; Ming-Dong Zhao; Hao-Jue Wang; Xia Li
Journal:  Front Physiol       Date:  2018-05-30       Impact factor: 4.566

5.  Effects of sangu decoction on osteoclast activity in a rat model of breast cancer bone metastasis.

Authors:  Bo Deng; Li-Qun Jia; Huang-Ying Tan; Xuan Yao; Fu-Yun Gao; Lin Pan; Jian Cui; Qing Xiang
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-06       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.